Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors

NCT03113188 is registered in ClinicalTrials.gov with CanBas Co. Ltd. as lead sponsor.

NCT NCT03113188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03113188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors
Lead sponsor
CanBas Co. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 25, 2017
Completion date
February 15, 2021
Enrollment
47 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors